Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Eli Lilly (NY:LLY)

817.93 -2.17 (-0.26%)
Streaming Delayed Price Updated: 2:58 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Understanding Market Records: Is This Sustainable Growth?
The global stock market is currently navigating an unprecedented era of record-breaking growth in late October 2025, a phenomenon largely orchestrated by the remarkable performance and pervasive... 
Via TokenRing AI
Topics Artificial Intelligence Economy Fraud
Nvidia Shatters Records: AI Powerhouse Hits $5 Trillion Market Cap, Reshaping Global Economy
In a historic moment for the technology and financial worlds, Nvidia Corporation (NASDAQ: NVDA) officially achieved an unprecedented $5 trillion market capitalization on Wednesday, October 29, 2025.... 
Via TokenRing AI
Topics Artificial Intelligence Economy Emissions
Earnings Outlook For Eli Lilly
 
Via Benzinga
Eli Lilly Advances AI And Access: Supercomputer With NVIDIA, Zepbound Via Walmart
Eli Lilly partners with NVIDIA to build a powerful AI supercomputer and teams up with Walmart to expand affordable Zepbound access nationwide. 
Via Benzinga
Topics Artificial Intelligence
Nvidia Shatters Records with $5 Trillion Market Cap, Cementing AI Revolution Leadership
Santa Clara, CA – October 29, 2025 – In a historic moment for the technology sector, Nvidia (NASDAQ: NVDA) has officially achieved an unprecedented $5 trillion market capitalization, becoming the first... 
Via MarketMinute
Topics Artificial Intelligence Economy
Nvidia's 2 Surprises; NVDA Soars On Trump-Fueled Hopes of China Blackwell Sales; Fed In Focus
Two Nvidia Shockers Please click here for an enlarged chart of NVIDIA Corp (NASDAQ:NVDA). 
Via Benzinga
Topics Economy
Nvidia's AI Reign: Fueling Market Gains and Forging a New Industrial Revolution
Nvidia (NASDAQ: NVDA) stands as the undisputed titan of the artificial intelligence (AI) era, its stock performance a primary catalyst for the recent, unprecedented surge in global financial markets.... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Eli Lilly Partners With Walmart To Expand Access To Popular Weight-loss Drug
Zepbound vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November. 
Via Stocktwits
1 Incredible Reason to Buy Novo Nordisk Stock (NVO) in November -- or Sooner
It offers compelling weight-loss drugs -- and a compelling stock price, too. 
Via The Motley Fool
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026?
This stock has caught fire after some recent events, but how long will that last? 
Via The Motley Fool
Eli Lilly (LLY) To Report Earnings Tomorrow: Here Is What To Expect
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be announcing earnings results this Thursday before market open. Here’s what investors should know. 
Via StockStory
1 Undervalued Growth Stock Down 8% to Buy Before 2026
This momentary pullback represents an excellent opportunity to buy this high-flying stock. 
Via The Motley Fool
Topics World Trade
Eli Lilly Partners With Nvidia To Build Pharma’s Most Powerful AI Supercomputer
The Nvidia-powered system aims to cut drug development times and boost innovation. 
Via Talk Markets
Topics Artificial Intelligence
Why Nvidia (NVDA) Stock Is Up Today
Shares of leading designer of graphics chips Nvidia (NASDAQ:NVDA) jumped 5.2% in the afternoon session after CEO Jensen Huang laid out an overwhelmingly bullish case for the company's future at a... 
Via StockStory
Topics Artificial Intelligence Government World Trade
Ken Paxton Alleges Johnson & Johnson Misled Mothers On Tylenol Safety
Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, alleging Tylenol was deceptively marketed as safe for pregnant women. 
Via Benzinga
Topics Lawsuit
Why NeoGenomics (NEO) Stock Is Trading Up Today
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 1.1% in the morning session after it reported third-quarter 2025 results where revenue beat Wall Street's expectations. 
Via StockStory
Topics World Trade
If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These
These two have been neglected by Wall Street too much. 
Via The Motley Fool
Eli Lilly & Co (NYSE:LLY) Presents a High Growth Momentum and Technical Breakout Opportunity
Eli Lilly (LLY) is a top growth momentum stock with accelerating earnings, strong technical ratings, and a positive breakout setup for investors. 
Via Chartmill
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers
As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Peering Into Eli Lilly and Co's Recent Short Interest
 
Via Benzinga
BDF-GESTION Trims Its Eli Lilly (LLY) Stake by 4,149 Shares
BDF-GESTION Trims Its Eli Lilly (LLY) Stake by 4,149 Shares 
Via The Motley Fool
What Is 1 of the Best Pharmaceutical Stocks to Buy Now?
This pharma giant is entering the rapidly expanding market for weight loss drugs. 
Via The Motley Fool
Down 15%, Should You Buy the Dip on Eli Lilly?
Lilly's stock has pulled back from its 2024 highs, but that doesn't mean the shares are cheap enough to buy. 
Via The Motley Fool
Topics Intellectual Property
Viking Therapeutics: High Risk, High Reward Play
Via MarketBeat
Should You Buy Eli Lilly Stock Before Oct. 30?
Long-term investors don't need to rush to buy Eli Lilly stock. 
Via The Motley Fool
Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal
Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash. 
Via Benzinga
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher?
The clinical-stage biotech is working on a new type of weight management drug. 
Via The Motley Fool
Eli Lilly And Co. Stock: Gains As $12.47-Per-Share Adverum Biotech Deal Expands Gene Therapy Portfolio
Eli Lilly stock rises as $12.47-per-share Adverum Biotech deal boosts its gene therapy ambitions and expands ophthalmology pipeline. 
Via Talk Markets
Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis
Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Olumiant in hair regrowth. 
Via Benzinga
Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections
Lilly (LLY) to acquire Adverum Biotechnologies (ADVM) for $12.47 per share, with potential CVR payments tied to future milestones. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.